+ Follow EUROPEAN MUTUAL RECOGNITION PROCEDURE Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 277248
[Title] => Drug for kidney transplants hits RP market
[Summary] => Novartis Healthcare Phils. Inc. has announced that its newest product especially designed to prevent organ rejection for kidney transplant patients hit the Philippine market last April.
The product was launched at the recently concluded Philippine Society of Nephrology dinner-symposium held at the EDSA Shangri-La Hotel.
[DatePublished] => 2005-05-12 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 196998
[Title] => New anti-cholesterol drug in the market
[Summary] => Management of coronary heart disease (CHD), a major cause of death in the Western world and commonly associated with atherosclerosis, recently got a new boost with the approval by Canadian authorities of Rosuvastatin for the management of primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia, conditions better known as "high cholesterol."
Canadian medical experts agree that low density lipoprotein (LDL-C), commonly known as the "bad" cholesterol, is the most significant contributory risk factor for atherosclerosis.
[DatePublished] => 2003-02-27 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 164478
[Title] => COPD therapy introduced in RP
[Summary] => The novel once-daily inhaled treatment tiotropium (Spiriva) for treating chronic obstructive pulmonary disease (COPD) has been introduced in the Netherlands and the Philippines. Launches in Germany, Sweden, Denmark and Finland will follow this month.
Spiriva (tiotropium) is approved as a bronchodilator for the maintenance treatment of COPD. Discovered and developed by Boehringer Ingelheim, Spiriva is the first once-daily inhaled therapy for COPD.
[DatePublished] => 2002-06-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
EUROPEAN MUTUAL RECOGNITION PROCEDURE
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 277248
[Title] => Drug for kidney transplants hits RP market
[Summary] => Novartis Healthcare Phils. Inc. has announced that its newest product especially designed to prevent organ rejection for kidney transplant patients hit the Philippine market last April.
The product was launched at the recently concluded Philippine Society of Nephrology dinner-symposium held at the EDSA Shangri-La Hotel.
[DatePublished] => 2005-05-12 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 196998
[Title] => New anti-cholesterol drug in the market
[Summary] => Management of coronary heart disease (CHD), a major cause of death in the Western world and commonly associated with atherosclerosis, recently got a new boost with the approval by Canadian authorities of Rosuvastatin for the management of primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia, conditions better known as "high cholesterol."
Canadian medical experts agree that low density lipoprotein (LDL-C), commonly known as the "bad" cholesterol, is the most significant contributory risk factor for atherosclerosis.
[DatePublished] => 2003-02-27 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 164478
[Title] => COPD therapy introduced in RP
[Summary] => The novel once-daily inhaled treatment tiotropium (Spiriva) for treating chronic obstructive pulmonary disease (COPD) has been introduced in the Netherlands and the Philippines. Launches in Germany, Sweden, Denmark and Finland will follow this month.
Spiriva (tiotropium) is approved as a bronchodilator for the maintenance treatment of COPD. Discovered and developed by Boehringer Ingelheim, Spiriva is the first once-daily inhaled therapy for COPD.
[DatePublished] => 2002-06-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
February 27, 2003 - 12:00am
